Omeros Settles Infringement Suit Against Lupin Over Proposed Omidria Generic

June 1, 2018: By Jon Swedien

Legal issueSeattle-based Omeros announced May 24 that it has signed an agreement with India-based Lupin that resolves patent litigation over a proposed generic for Omeros’ Omidria.

Omeros sued Lupin after the Indian company’s US-based subsidiary, Lupin Pharmaceuticals, began pursuing an abbreviated new drug application with the US FDA for a generic version of Omidria.

Surgeons use Omidria (phenylephrine and ketorolac injection) during cataract surgery to maintain pupil size by preventing miosis and for reducing postoperative ocular pain.

In 2017, Omeros settled litigation over an abbreviated new drug application filing by Par Sterile Products and Par Pharmaceutical, Omeros said.

As with the Par settlement, Lupin acknowledged and confirmed the validity of all Omeros’ Omidria patents, Omeros said. Omeros did not disclose if there were any payments included in the deal.

Omidria’s patent protection expires Oct. 23, 2033.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023